Skip to main content
SpringerLink
Log in

Renal, bladder, and prostate cancers: gene therapy

  • Chapter
Diagnosis and Treatment of Genitourinary Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR,volume 88))

Abstract

Human gene therapy has emerged as a major research endeavor in experimental therapeutics for cancer. Gene therapy as clinical research is still in its earliest stages. Nevertheless, in the past three years, over 200 peer-reviewed manuscripts in human gene therapy have been published. Furthermore, 120 clinical protocols of human gene therapy have gained approval of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) since the treatment of the first patient with human gene therapy in 1990. Currently, over 14 clinical trials of therapeutic gene transfer in the treatment of urologic malignancies are underway worldwide, and more are under active development or pending approval (Table 14-1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kelley WN (1994). The impact of gene therapy on medicine and society: gene therapy for neoplastic diseases. Ann NY Aced Sci 76:12–19.

    Article  Google Scholar 

  2. Watson JD, Crick FH (1953). Molecular structure of nucleic acids. A structure for doexyribose nucleic acid. Nature 171:737–738.

    Article  PubMed  CAS  Google Scholar 

  3. Watson JD, Crick FH (1953). Genetic implications of the structure of deoxyribo nucleic acid. Nature 171:737–738.

    Article  PubMed  CAS  Google Scholar 

  4. Tolstoshev P (1993). Gene therapy, concepts, current trials and future directions. Annu Rev Pharmacol Toxicol 32:573–596.

    Article  Google Scholar 

  5. Sikora K (1994). Genes, dreams, and cancer. Br Med J 308:1217–1221.

    Article  CAS  Google Scholar 

  6. Mulligan R (1993). The basic science of gene therapy. 260:926–932.

    CAS  Google Scholar 

  7. Johnson P, Miyanohara A, Levine F, Cahill T, Friedmann T (1992). Cytotoxicity of a replication-defection mutant of herpes simplex virus type 1. J Virol 66:2952–2965.

    PubMed  CAS  Google Scholar 

  8. Jones N, Shenk T (1979). Isolation of adenovirus type 5 host range deletion mutants defective for transformation to rat embryo cells. Cell 17:683–689.

    Article  PubMed  CAS  Google Scholar 

  9. Danos O, Mulligan R (1988). Safe and efficient generation of recombinant retrovirus with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460–6464.

    Article  PubMed  CAS  Google Scholar 

  10. Miller A (1990). Retrovirus packaging cells. Hum Gene Ther 1:5–14.

    Article  PubMed  CAS  Google Scholar 

  11. Kozarsky K, Wilson J (1993). Gene therapy: adenovirus vectors. Curr Opinion Genet Dev 3:399–503.

    Article  Google Scholar 

  12. Cornetta K, Moen R, Culver K, Morgan R, McLacherlin J, Sturm S, Selegue J, London W, Blaese R, Anderson W (1990). Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther 1:15–30.

    Article  PubMed  CAS  Google Scholar 

  13. Roe T, Reynolds T, Yu G, Brown P (1993). Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12:2099–2108.

    PubMed  CAS  Google Scholar 

  14. Kotin RM, Siniscalco M, Samulski R, Zhu X, Hunter L, Laughlin C, McLaughlin S, Muzyczka N, Rocchi M, Berns K (1990). Site-specific integration of adeno-associated virus. Proc Natl Acad Sci USA 87:2211–2215.

    Article  PubMed  CAS  Google Scholar 

  15. Muzyczka N (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158:97–129.

    Article  PubMed  CAS  Google Scholar 

  16. Anderson W (1992). Human gene therapy. Science 256:808–813.

    Article  PubMed  CAS  Google Scholar 

  17. Moss B, Flexner C (1987). Vaccinia virus expression vectors. Annu Rev Immunol 5:305–324.

    Article  PubMed  CAS  Google Scholar 

  18. Culver KW, Blaese RM (1994). Gene therapy for cancer. TIG 10(5):174–178.

    Article  PubMed  CAS  Google Scholar 

  19. Friend SH, Bernards R, Rogeli S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–646.

    Article  PubMed  CAS  Google Scholar 

  20. Latif F, Tory K, Gnarra J, et al. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320.

    Article  PubMed  CAS  Google Scholar 

  21. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221.

    Article  PubMed  CAS  Google Scholar 

  22. Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61:759–767.

    Article  PubMed  CAS  Google Scholar 

  23. Rose EA, Glaser T, Jones C, et al. (1990). Complete physical map of the WAGR region of 11p13 localizes a candidate Wilm’s tumor gene. Cell 60:495–508.

    Article  PubMed  CAS  Google Scholar 

  24. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JL, Isaacs WB (1990). Allelic loss of chromosome 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751–8755.

    Article  PubMed  CAS  Google Scholar 

  25. Presti JC Jr, Reuter VE, Galan T, Fair WR, Cordon-Cardo C (1991). Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51:5405–5409.

    PubMed  Google Scholar 

  26. Yang C, Cirielli C, Capogrossi MC, Passaniti A (1995). Adenoviirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55:4210–4213.

    PubMed  CAS  Google Scholar 

  27. Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenback AC, Hseih JT (1995). Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in andro-gen-independent human prostate cancer therapy: a preclinical study. Cancer Res 55:2831–2836.

    PubMed  CAS  Google Scholar 

  28. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT (1995). Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55:2024–2028.

    PubMed  CAS  Google Scholar 

  29. Werthman P, Drazan K, Csete M, Bullington D, Zhang W, Rosenthal J, Shaked A (1994). Adenoviral-mediated transfer of human p53 tumor suppressor gene to rat bladder in vivo. J Urol 151:389A.

    Google Scholar 

  30. Sanda M, Ayyagari S, Jaffee E, Epstein J, Clift S, Cohen L, Drannoff G, Pardoll D, Mulligan R, Simons J (1994). Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622–628.

    PubMed  CAS  Google Scholar 

  31. Vieweg J, Rosenthal F, Bannerji R, Heston W, Fair W, Gansbacher B, Gilboa E (1994). Immunotherapy for prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765.

    PubMed  CAS  Google Scholar 

  32. Carducci MA, Ayyagari SR, Sanda MG, Simons JW (1995). Gene therapy for human prostate cancer: translational research in the hormone refractory Dunning prostate cancer model. Cancer 75:2013–2020.

    Article  Google Scholar 

  33. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713–716.

    Article  PubMed  CAS  Google Scholar 

  34. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 90:3539–3543.

    Article  PubMed  CAS  Google Scholar 

  35. Bubenik J, Voitenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D, Simova J, Jandlova T (1988). Local administration of cells containing an inserted II-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol Lett 19:279–282.

    Article  PubMed  CAS  Google Scholar 

  36. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403.

    Article  PubMed  CAS  Google Scholar 

  37. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990). Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217–1224.

    Article  PubMed  CAS  Google Scholar 

  38. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990). Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820–7825.

    PubMed  CAS  Google Scholar 

  39. Porgador A, Tzehoval E, Katz, A, Vadai E, Revel M, Feldman M, Eisenbach L (1992). Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679–3686.

    PubMed  CAS  Google Scholar 

  40. Cordon-Cardu C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M (1991). Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372–6380.

    Google Scholar 

  41. Sanda M, Simons J, Pardol D, Restifo N (1993). Human prostate cells escape immunity via reversible heterogeneous defects in antigen processing. J Urol 149:374A.

    Google Scholar 

  42. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamanstein T, Blankenstein T (1993). Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 53:714–716.

    PubMed  CAS  Google Scholar 

  43. Steiner M, Barrack E (1992). Transforming growth factor-Bl overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6:15–25.

    Article  PubMed  CAS  Google Scholar 

  44. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993). Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 177:1127–1134.

    Article  PubMed  CAS  Google Scholar 

  45. Moody B, Lazenby A, Ewing C, Isaacs W (1994). Interleukin-2 transfected prostate cancer cells generate a local anti-tumor effect in vivo. Prostate 24:244–251.

    Article  PubMed  CAS  Google Scholar 

  46. Levitsky H, Lazenby A, Hayashi R, Pardoll D (1994). In vivo priming of 2 distinct antitumor effector populations: the role of MHC class-I expression. J Exp Med 179:1215–1224.

    Article  PubMed  CAS  Google Scholar 

  47. Sanda M, Carducci M, Ayyagari S, Kim W, Cohen L, Mulligan R, Pardoll D, Simons J (1994). Gene therapy for human prostate cancer: efficacy in animal models and feasibility for human trials. J Urol 151:492A.

    Google Scholar 

  48. Belldegrun A, Tso C, Sakata T, et al. (1993). Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 85:207–216.

    Article  PubMed  CAS  Google Scholar 

  49. Furman P, McGuirt P, Keller P, Fyfe J, Elion G (1980). Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology 102:420–430.

    Article  PubMed  CAS  Google Scholar 

  50. St Clair M, Lambe C, Furman P (1987). Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herped virus genetic information. Antimicrob Agents Chemother 31:844–849.

    Article  PubMed  CAS  Google Scholar 

  51. Mattews T, Boehme R (1988). Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10(Suppl 3):S490–S494.

    Article  Google Scholar 

  52. Freeman S, Abboud C, Whartenby K, Packman C, Koeplin D, Moolten F, Abraham G (1993). The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 52:5274–5283.

    Google Scholar 

  53. Culver K, Ram Z, Wallbridge, S, Ishii H, Oldfield E, Blaese R (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550–1552.

    Article  PubMed  CAS  Google Scholar 

  54. Moolten F, Wells J (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82:297–300.

    Article  PubMed  CAS  Google Scholar 

  55. Smythe W, Hwang H, Amin K, Eck S, Davidson B, Wilson J, Kaiser L, Albelda S (1994). Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSTtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54:2055–2059.

    PubMed  CAS  Google Scholar 

  56. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann J, Klatzmann D (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90:7024–7028.

    Article  PubMed  CAS  Google Scholar 

  57. Takamiya Y, Short M, Ezzeddine Z, Moolton F, Breakefield X, Martuza R (1992). Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Naurosci Res 33:493–503.

    Article  CAS  Google Scholar 

  58. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83–88.

    PubMed  CAS  Google Scholar 

  59. Culver KW, Van Gilder J, Link CJ, Carlstrom T, Buroker T, Yuh W, Koch K, Schabold K, et al. (1994). Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 5:343–379.

    Article  PubMed  CAS  Google Scholar 

  60. Chen SH, Shine HS, Goodman JC, Grossman RG, Woo SL (1994). Gene therapy for brain tumors: regression of experimental gliomas by adenovirius mediated gene transfer in vivo. Proc Natl Acad Sci USA 91:3057–3059.

    Google Scholar 

  61. Bi WL, Parysek LM, Warnick R, Stambrook, PI (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum Gene Ther 4:725–731.

    Article  PubMed  CAS  Google Scholar 

  62. Ram Z, Walbridge S, Shawker T, Culver KW, Blasese RM, Oldfield EH (1994). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81:256–260.

    Article  PubMed  CAS  Google Scholar 

  63. Isaacs JT, Landniu PI, Berges R, Martikainen P, Kyprianou N, English HF (1992). Androgen regulation of programmed cell death of normal and malignant prostate cells. J Androl 13:455–484.

    Google Scholar 

  64. Taneja S, Gelldegrun A, Dardashti K, Cohan P, Dekernion J, Pang S (1994). Construction of a prostate specific antigen promoter-driven gene transfer vector: a novel strategy for target specific gene therapy in prostate cancer. J Urol 151:491A.

    Google Scholar 

  65. Fujiwara T, Grimm E, Roth J (1994). Gene therapeutics and gene therapy for cancer. Curr Opinion Oncol 6:96–105.

    Article  CAS  Google Scholar 

  66. Anderson W (1992). Editorial: uses and abuses of human gene transfer. Hum Gene Ther 3:1–2.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michael A. Carducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan W. Simons
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, 48109-0680, USA

    Kenneth J. Pienta

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Carducci, M.A., Simons, J.W. (1996). Renal, bladder, and prostate cancers: gene therapy. In: Pienta, K.J. (eds) Diagnosis and Treatment of Genitourinary Malignancies. Cancer Treatment and Research, vol 88. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6343-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6343-3_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7913-3

  • Online ISBN: 978-1-4615-6343-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation